🇺🇸 FDA

Company profile · Sponsor

Phathom

Phathom Pharmaceuticals

PHAT · NYSE pharma FLORHAM PARK, NJ, USA
Pipeline
11
Drugs
1
Patents
8

Quick answer

Phathom (PHAT) is a pharma company. headquartered in FLORHAM PARK, NJ, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 1 drug, and 8 patents to this profile..

Company facts

Ticker PHAT
Exchange NYSE
Company type pharma
Headquarters FLORHAM PARK, NJ, USA
SEC CIK 0001783183

Pipeline (11)

Search pipeline →

  1. Vonoprazan

    Phathom

    Non-Erosive Gastro-Esophageal Reflux Disease

    phase 3 small molecule completed

    2 trials

  2. Vonoprazan

    Phathom

    Erosive Esophagitis

    phase 3 small molecule completed

    2 trials

  3. Vonoprazan

    Phathom

    Helicobacter Pylori Infection

    phase 3 small molecule completed

    1 trial

  4. Vonoprazan

    Phathom

    Eosinophilic Esophagitis

    phase 2 small molecule active

    1 trial

  5. Vonoprazan

    Phathom

    Healthy Volunteers

    phase 1 small molecule completed

    2 trials

  6. Vonoprazan

    Phathom

    Gastroesophageal Reflux

    phase 1 small molecule completed

    1 trial

  7. Vonoprazan

    Phathom

    Gastroesophageal Reflux Disease

    phase 1 small molecule completed

    1 trial

  8. Vonoprazan

    Phathom

    Healthy Participants

    phase 1 small molecule terminated

    2 trials

  9. Vonoprazan ODT-1 or ODT-2 without Water

    Phathom

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  10. PYTEST® 14C-Urea Breath Test

    Phathom

    H Pylori Infection

    approved small molecule active

    1 trial

  11. PYTEST® 14C-Urea Capsule Breath Test (at Home)

    Phathom

    H. Pylori Infection

    approved small molecule active

    1 trial

Drugs (1)

Search drugs →

  1. vonoprazan fumarate

    VOQUEZNA

    ORAL approved

Patents (8)

Search patents →

  1. US 9198961

    Bacterial extract for digestive or urinary tract disorders and process for its preparation

    Expires Mon Nov 26 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 9017743

    Bacterial extract for digestive or urinary tract disorders and process for its preparation

    Expires Mon Apr 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 8618080

    Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines

    Expires Mon Dec 26 2033 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 8236522

    Bacterial extract for digestive or urinary tract disorders and process for its preparation

    Expires Mon Aug 02 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 8173133

    Acyl pseudodipeptides which carry a functionalized auxiliary arm

    Expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7915240

    Immunomodulatory compounds and treatment of diseases related to an overproduction of inflammatory cytokines

    Expires Mon Mar 24 2031 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7799762

    Acyl pseudodipeptides which carry a functionalised auxialiary arm

    Expires Mon Sep 16 2030 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7157092

    Acyl pseudodipeptides, preparation method and pharmaceutical compositions containing same

    Expires Mon Dec 28 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Phathom?

Phathom (PHAT) is a pharma company. headquartered in FLORHAM PARK, NJ, USA. listed on NYSE. NovaPharmaNews links 11 pipeline programs, 1 drug, and 8 patents to this profile..

What pipeline programs does Phathom sponsor?

We track 11 ClinicalTrials.gov-linked programs for Phathom, including Vonoprazan and 10 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Phathom company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.